| 2008 |
Dr. Barbara Römer |
2001/20/EC - A European Directive? Major Regulatory Objectives for a real Harmonisation in Europe *** |
|
|
| 2008 |
Jörg Schneidereit |
An Approach to Abbreviated New Drug Applications (ANDA) and Question based Review (QbR) *** |
|
|
| 2008 |
Sandra Schneidereit, (geb. Nehlsen) |
The Escitalopram Case: A Comprehensive Strategy Allowing for Early Market Access of a Generic Drug |
|
|
| 2008 |
Carola Seidel |
Das IQWiG als neuer Eckpfeiler bei der Entscheidungsfindung des Portfolios der Generikaunternehmen |
|
|
| 2008 |
Dr. Patricia Stöhr |
The Regulatory Environment for Vaccine Development - a Challenge for Industry |
|
|
| 2008 |
Florian Strohmaier |
Evaluation of the legal basis of biological and biotechnological product applications in Europe and US and discussion of consequences for similar biological medicinal product applications |
|
|
| 2008 |
Dr. Sanjiv Verma |
The Regulatory Framework concerning the Import of Medicinal Products in India and in the European Union (e.g. Germany) |
|
|
| 2008 |
Dr. Benita von Glahn |
Post marketing Activities in Japan compared to EU and USA |
|
|
| 2008 |
Dr. Martin Wendland |
Regulatory guidance on comparability studies for biological products following changes to the manufacturing process and analytical procedures |
|
|
| 2008 |
Frank Zimmermann |
The Centralised Procedure from the Micro, Small and Medium-sized Enterprise's Perspective and Specific Obstacles of SMEs *** |
|
|
| 2007 |
Dr. Joachim Ahlert |
ICH Q8: Pharmaceutical Development. Regulatory Requirements Directed by the New Note for Guidance (EMEA/CHMP/167068/2004) in Comparison to the Previous Guideline (CPMP/QWP/155/96). A Critical View from the Generic Pharmaceutical Industry. *** |
|
|
| 2007 |
Dr. Ludger Benning |
Electronic Submission and the MRP/DCP: How to Compile a Dossier That Will be Accepted at the European Agencies *** |
|
|
| 2007 |
Dr. Michael Bernhard |
Quality attributes of biopharmaceuticals: The impact of glycosylation *** |
|
|
| 2007 |
Dr. Georg Brauers |
Regulatory Aspects of Pharmacogenomics in Clinical Drug Development *** |
|
|
| 2007 |
Jörg Cselovszky |
The New Regulatory Framework for Health Claims in the Eurpean Union Impact on the Demarcation of Food to Medicinal Products? *** |
|
|
| 2007 |
Claudia Fischer |
Investigational Medicinal Product Dossier (IMPD): CHMP/QWP/185401/2004-Guideline (Note for Guidance on the Requirements to the Chemical and Pharmaceutical Quality Documentation concerning Investigational Medicinal Products in Clinical trials): Comparison of requirements described in this guideline and in additional national guidance documents from exemplary EU countries and the emerging country India. Discussion of the impact on the compilation of a global IMPD for a multi-centre study |
|
|
| 2007 |
Ellen Frey-Stanislawski |
Revision of the Variation Regulations Commission Regulation (EC) No. 1084/2003 and No. 1085/2003 - Industry-Proposals and Consultation Paper from the European Commission, Impact on Industry and Health Authorities *** |
|
|
| 2007 |
Dr. Ulrich Fritsche |
An Overview of the Regulatory Framework of Fixed Dose Combination Medicinal Products (FDC) |
|
|
| 2007 |
Lena Gebert |
Impfstoffe für den Menschen - Ein Leitfaden über die besonderen arzneimittelrechtlichen Regelungen aus dem Arzneimittelgesetz *** |
|
|
| 2007 |
Anneke Hackling |
Clinical Trials in China |
|
|